Blood test to predict immunotherapy response in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is looking at a blood test to predict how well combined immunotherapy and chemotherapy will work in people with advanced lung cancer. It uses a new marker called ETASTs to help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IIIB or IV) non-small cell lung cancer.
- Your treatment plan includes immunotherapy (a PD-1 inhibitor) plus platinum-based chemotherapy.
- You are between 18 and 80 years old and in fairly good health (ECOG 0 or 1).
- Your blood counts and kidney/liver function meet the study's minimal safety levels.
- You have at least one tumor that can be measured on a CT scan, and no untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This trial studies whether a simple blood test can predict how well your immune system will respond to immunotherapy (such as Keytruda or Opdivo). You may qualify if you have lung cancer (NSCLC) or advanced melanoma and are about to start this type of treatment for the first time.
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This trial is for people with stage IIA to IIIB non-small cell lung cancer that can be removed by surgery. It tests if certain white blood cells (neutrophils) can help predict how well chemotherapy combined with immunotherapy works before surgery.
This study looks for blood markers that can predict how well certain lung cancer treatments work before surgery. By joining, you help find a simple blood test to guide personalized care.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.